{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:58:05Z","timestamp":1788562685144,"version":"build-2803163510"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/hr.2016.85","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T09:19:32Z","timestamp":1468487972000},"page":"21-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Dihydropyridine calcium channel blockers and renal disease"],"prefix":"10.1038","volume":"40","author":[{"given":"Nicol\u00e1s R","family":"Robles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"BFhr201685_CR1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM199601043340103","volume":"334","author":"MJ Klag","year":"1996","unstructured":"Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Ford CE, Shulman NB, Stamler J . Blood pressure and endstage renal disease in men. N Engl J Med 1996; 334: 13\u201318.","journal-title":"N Engl J Med"},{"key":"BFhr201685_CR2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/00004872-199611000-00001","volume":"14","author":"LM Ruilope","year":"1996","unstructured":"Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL . Blood pressure and renal function: therapeutic implications. J Hypertens 1996; 14: 1259\u20131263.","journal-title":"J Hypertens"},{"key":"BFhr201685_CR3","first-page":"105","volume-title":"Calcium Channel Blockers and Renal Disease","author":"NR Robles","year":"2009","unstructured":"Robles NR . Calcium antagonists and renal disease. In: Robles NR (ed). Calcium Channel Blockers and Renal Disease. Nova Science Publishers: New York, USA. 2009, pp 105\u2013133."},{"key":"BFhr201685_CR4","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/ndt\/12.11.2244","volume":"12","author":"N Tarif","year":"1997","unstructured":"Tarif N, Bakris GL . Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997; 12: 2244\u20132250.","journal-title":"Nephrol Dial Transplant"},{"key":"BFhr201685_CR5","doi-asserted-by":"crossref","first-page":"6F","DOI":"10.1016\/0002-9149(92)90182-X","volume":"70","author":"A Schwartz","year":"1992","unstructured":"Schwartz A . Molecular and cellular aspects of calcium channel antagonism. Am J Cardiol 1992; 70: 6F\u20138F.","journal-title":"Am J Cardiol"},{"key":"BFhr201685_CR6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ki.1994.255","volume":"46","author":"L Gaber","year":"1994","unstructured":"Gaber L, Walton C, Brown S, Bakris GL . Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994; 46: 161\u2013169.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR7","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/01.HYP.37.5.1268","volume":"37","author":"KA Griffin","year":"2001","unstructured":"Griffin KA, Picken M, Bakris GL, Bidani AK . Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension 2001; 37: 1268\u20131272.","journal-title":"Hypertension"},{"key":"BFhr201685_CR8","volume-title":"Calcium Channel Blockers and Renal Disease","author":"AF Rubio-Guerra","year":"2009","unstructured":"Rubio-Guerra AF . Non-dihydropyridinic calcium antagonists and renal disease. In: Robles NR (ed). Calcium Channel Blockers and Renal Disease. Nova Science Publishers: New York, USA. 2009."},{"key":"BFhr201685_CR9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/01.HYP.0000184541.24700.c7","volume":"46","author":"S Nathan","year":"2005","unstructured":"Nathan S, Pepine CJ, Bakris GL . Calcium antagonist. Effects on cardio-renal risk in hypertensive patients. Hypertension 2005; 46: 637\u2013642.","journal-title":"Hypertension"},{"key":"BFhr201685_CR10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000381480","volume":"130","author":"E Daina","year":"2015","unstructured":"Daina E, Cravedi P, Alpa M, Roccatello D, Gamba S, Perna A, Gaspari F, Remuzzi G, Ruggenenti P . A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study. Nephron 2015; 130: 13\u201320.","journal-title":"Nephron"},{"key":"BFhr201685_CR11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.diabres.2005.02.019","volume":"70","author":"M P\u00e9rez-Maraver","year":"2005","unstructured":"P\u00e9rez-Maraver M, Carrera MJ, Mical\u00f3 T, Sahun M, Vinzia C, Soler J, Montanya E . Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment. Diabetes Res Clin Pract 2005; 70: 13\u201319.","journal-title":"Diabetes Res Clin Pract"},{"key":"BFhr201685_CR12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1523-1755.1998.00055.x","volume":"54","author":"AC Smith","year":"1998","unstructured":"Smith AC, Toto R, Bakris GL . Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889\u2013896.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR13","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ki.1996.480","volume":"50","author":"GL Bakris","year":"1996","unstructured":"Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S . Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641\u20131650.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR14","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ki.1996.480","volume":"50","author":"GL Bakris","year":"1995","unstructured":"Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S . Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1995; 50: 1641\u20141650.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.HYP.29.3.744","volume":"29","author":"GL Bakris","year":"1997","unstructured":"Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R . Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29: 744\u2013750.","journal-title":"Hypertension"},{"key":"BFhr201685_CR16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.jhh.1001279","volume":"15","author":"R Fernandez","year":"2001","unstructured":"Fernandez R, Garcia J, Rodriguez JC, Garrido J, Redon J . Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria. A randomized double blind study. J Hum Hypertens 2001; 15: 849\u2013856.","journal-title":"J Hum Hypertens"},{"key":"BFhr201685_CR17","first-page":"310","volume":"47","author":"RA Preston","year":"1997","unstructured":"Preston RA, Materson BJ, Reda DJ, Hamburger RJ, Williams DW, Smith MH . Proteinuria in mild to moderate hypertension: results of the VA cooperative study of six antihypertensive agents and placebo. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Clin Nephrol 1997; 47: 310\u2013315.","journal-title":"Clin Nephrol"},{"key":"BFhr201685_CR18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Ilieve IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G . Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminiria in type 2 diabetes. N Engl J Med 2004; 351: 1941\u20131951.","journal-title":"N Engl J Med"},{"key":"BFhr201685_CR19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0272-6386(03)00410-4","volume":"42","author":"R Boero","year":"2003","unstructured":"Boero R, Rollino C, Massara C, Berto IM, Perosa P, Vagelli G, Lanfranco G, Quarello F . The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study. Am J Kidney Dis 2003; 42: 67\u201375.","journal-title":"Am J Kidney Dis"},{"key":"BFhr201685_CR20","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","volume":"65","author":"GL Bakris","year":"2004","unstructured":"Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A . Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004; 65: 1991\u20132002.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR21","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1681\/ASN.V1113","volume":"1","author":"C Sweeney","year":"1990","unstructured":"Sweeney C, Shultz P, Raij L . Interactions of the endothelium and mesangium in glomerular injury. J Am Soc Nephrol 1990; 1: S13\u2013S20.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 36","key":"BFhr201685_CR22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0002-9343(85)90076-2","volume":"79","author":"L Raij","year":"1985","unstructured":"Raij L, Keane W . Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 1985; 79 (Suppl 36): 24\u201330.","journal-title":"Am J Med"},{"key":"BFhr201685_CR23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/00004872-199611000-00001","volume":"14","author":"LM Ruilope","year":"1996","unstructured":"Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL . Blood pressure and renal function: therapeutic implications. J Hypertens 1996; 14: 1259\u20131263.","journal-title":"J Hypertens"},{"key":"BFhr201685_CR24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000045633","volume":"85","author":"T Sugiura","year":"2000","unstructured":"Sugiura T, Imai E, Moriyama T, Horio M, Hori M . Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: possible mechanism of suppression of AP-1 and CREB activities. Nephron 2000; 85: 71\u201380.","journal-title":"Nephron"},{"key":"BFhr201685_CR25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1159\/000065266","volume":"22","author":"T Ono","year":"2002","unstructured":"Ono T, Liu N, Kusano H, Nogaki F, Makino T, Muso E, Sasayama S . Broad antiproliferative effects of benidipine on cultured human mesangial cells in cell cycle phases. Am J Nephrol 2002; 22: 581\u2013586.","journal-title":"Am J Nephrol"},{"key":"BFhr201685_CR26","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1073\/pnas.89.9.4071","volume":"89","author":"M Roth","year":"1992","unstructured":"Roth M, Keul R, Emmons LR, Horl WH, Block LH . Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci USA 1992; 89: 4071\u20134075.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFhr201685_CR27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1291\/hypres.23.521","volume":"23","author":"M Hayashi","year":"2000","unstructured":"Hayashi M, Yamaji Y, Nakazato Y, Saruta T . The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangial cells. Hypertens Res 2000; 23: 521\u2013525.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.CIR.0000021924.02006.BA","volume":"106","author":"K Fukuo","year":"2002","unstructured":"Fukuo K, Yang J, Yasuda O, Mogi M, Suhara T, Sato N, Suzuki T, Morimoto S, Ogihara T . Nifedipine indirectly upregulates superoxide dismutase expression in endotelial cells via vascular smooth muscle cell-dependent pathways. Circulation 2002; 106: 356\u2013361.","journal-title":"Circulation"},{"key":"BFhr201685_CR29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(97)00158-7","volume":"30","author":"L Chen","year":"1997","unstructured":"Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL . Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of anti-atherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30: 569\u2013575.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr201685_CR30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1096\/fasebj.11.2.9039953","volume":"11","author":"HR Lander","year":"1997","unstructured":"Lander HR . An essential role for free radicals and derived species in signal transduction. FASEB J 1997; 11: 118\u2013124.","journal-title":"FASEB J"},{"key":"BFhr201685_CR31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0891-5849(92)90025-C","volume":"12","author":"FTM Van Amsterdam","year":"1992","unstructured":"Van Amsterdam FTM, Roveri A, Maiorino M, Ratti E, Ursini F . Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Rad Biol Med 1992; 12: 183\u2013187.","journal-title":"Free Rad Biol Med"},{"key":"BFhr201685_CR32","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/00004872-199715120-00065","volume":"15","author":"L Cominacini","year":"1997","unstructured":"Cominacini L, Garbin U, Fratta Pasini A, Paulon T, Davoli A, Campagnola M, Marchi E, Pastorino AM, Gaviraghi G, Lo Cascio V . Lacidipine inhibits the activation of the transcription factor Nf-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endotelial cells. J Hypertens 1997; 15: 1633\u20131639.","journal-title":"J Hypertens"},{"issue":"Suppl 4","key":"BFhr201685_CR33","first-page":"S17","volume":"18","author":"M Epstein","year":"1998","unstructured":"Epstein M . Calcium antagonists and renal protection: Emerging perspectives. J Hypertens 1998; 18 (Suppl 4): S17\u2013S25.","journal-title":"J Hypertens"},{"key":"BFhr201685_CR34","first-page":"83","volume":"12","author":"DP Brooks","year":"1997","unstructured":"Brooks DP . Endothelin: the \u2018prime suspect\u2019 in kidney disease. News Physiol Sci 1997; 12: 83\u201389.","journal-title":"News Physiol Sci"},{"key":"BFhr201685_CR35","doi-asserted-by":"crossref","first-page":"PL1","DOI":"10.1016\/0024-3205(95)02259-7","volume":"58","author":"K Fujita","year":"1995","unstructured":"Fujita K, Matsumura Y, Miyazaki Y, Hashimoto N, Takaoka M, Morimoto S . ETA receptor-mediated role of endothelin in the kidney of DOCA-salt hypertensive rats. Life Sci 1995; 58: PL1\u2013PL7.","journal-title":"Life Sci"},{"key":"BFhr201685_CR36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0008-6363(95)00200-6","volume":"31","author":"B Hocher","year":"1996","unstructured":"Hocher B, Rohmeiss P, Zart R, Diekmann F, Vogt V, Metz D, Fakhury M, Gretz N, Bauer C, Koppenhagen K, Neumayer HH, Distler A . Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc Res 1996; 31: 499\u2013510.","journal-title":"Cardiovasc Res"},{"key":"BFhr201685_CR37","first-page":"F1166","volume":"271","author":"K Gurbanov","year":"1996","unstructured":"Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better OS, Winaver J . Differential regulation of renal regional blood flow by endothelin-1. Am J Physiol 1996; 271: F1166\u2013F1172.","journal-title":"Am J Physiol"},{"key":"BFhr201685_CR38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0014-2999(89)90372-5","volume":"166","author":"K Tsuchiya","year":"1989","unstructured":"Tsuchiya K, Naruse M, Sanaka T, Naruse K, Nitta K, Demura H, Sugino N . Effects of endothelin on renal regional blood flow in dogs. Eur J Pharmacol 1989; 166: 541\u2013543.","journal-title":"Eur J Pharmacol"},{"key":"BFhr201685_CR39","first-page":"R1","volume":"273","author":"AWJr Cowley","year":"1997","unstructured":"Cowley AW Jr . Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol 1997; 273: R1\u2013R15.","journal-title":"Am J Physiol"},{"key":"BFhr201685_CR40","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM199110033251404","volume":"325","author":"A Lerman","year":"1991","unstructured":"Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC . Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997\u20131001.","journal-title":"N Engl J Med"},{"key":"BFhr201685_CR41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/ajh\/4.4.303","volume":"4","author":"EL Schiffrin","year":"1991","unstructured":"Schiffrin EL, Thibault G . Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4: 303\u2013308.","journal-title":"Am J Hypertens"},{"key":"BFhr201685_CR42","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-201X.2004.01314.x","volume":"181","author":"M Salomonsson","year":"2004","unstructured":"Salomonsson M, Sorensen CM, Arendshorst WJ, Steendahl J, Holstein-Rathlou NH . Calcium handling in afferent arterioles. Acta Physiol Scand 2004; 181: 421\u2013429.","journal-title":"Acta Physiol Scand"},{"key":"BFhr201685_CR43","volume-title":"Calcium Channel Blockers and Renal Disease","author":"S Richard","year":"2009","unstructured":"Richard S . Effects of calcium antagonists in renal hemodynamics. In: Robles NR (ed). Calcium Channel Blockers and Renal Disease. Nova Science Publishers: New York, USA. 2009."},{"key":"BFhr201685_CR44","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.RES.87.10.896","volume":"87","author":"PB Hansen","year":"2000","unstructured":"Hansen PB, Jensen LB, Andreasen D, Friis UG, Skott O . Vascular smooth muscle cells express the \u03b11A subunit of a P-\/Q-type voltage-dependent Ca2+ channel, and it is functionally important in renal afferent arterioles. Circ Res 2000; 87: 896\u2013902.","journal-title":"Circ Res"},{"key":"BFhr201685_CR45","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF00374372","volume":"431","author":"S Diochot","year":"1995","unstructured":"Diochot S, Richard S, Baldy-Moulinier M, Nargeot J, Valmier J . Dihydropyridines, phenylalkylamines and benzothiazepines block N-, P\/Q- and R-type calcium currents. Pflugers Arch 1995; 431: 10\u201319.","journal-title":"Pflugers Arch"},{"issue":"Pt 2","key":"BFhr201685_CR46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1113\/jphysiol.1994.sp020286","volume":"479","author":"D Neveu","year":"1994","unstructured":"Neveu D, Quignard JF, Fernandez A, Richard S, Nargeot J . Differential beta-adrenergic regulation and phenotypic modulation of voltage-gated calcium currents in rat aortic myocytes. J Physiol 1994; 479 (Pt 2): 171\u2013182.","journal-title":"J Physiol"},{"key":"BFhr201685_CR47","doi-asserted-by":"crossref","first-page":"H582","DOI":"10.1152\/ajpheart.2001.280.2.H582","volume":"280","author":"F Gustafsson","year":"2001","unstructured":"Gustafsson F, Andreasen D, Salomonsson M, Jensen BL, Holstein-Rathlou N . Conducted vasoconstriction in rat mesenteric arterioles: role for dihydropyridine-insensitive Ca2+ channels. Am J Physiol Heart Circ Physiol 2001; 280: H582\u2013H590.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFhr201685_CR48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000072054","volume":"23","author":"K Hayashi","year":"2003","unstructured":"Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T . Role of actions of calcium antagonists on efferent arterioles\u2014with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229.","journal-title":"Am J Nephrol"},{"key":"BFhr201685_CR49","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/00004872-200111000-00014","volume":"19","author":"M Honda","year":"2001","unstructured":"Honda M, Hayashi K, Matsuda H, Kubota E, Tokuyama H, Okubo K, Sugino N . Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens 2001; 19: 2031.","journal-title":"J Hypertens"},{"key":"BFhr201685_CR50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.fjc.0000154374.88283.15","volume":"45","author":"T Furukawa","year":"2005","unstructured":"Furukawa T, Nukada T, Miura R, Ooga K, Honda M, Watanabe S, Koganesawa S, Isshiki T . Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005; 45: 241.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFhr201685_CR51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.HYP.38.3.343","volume":"38","author":"Y Ozawa","year":"2001","unstructured":"Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T . Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydronephrotic kidney. Hypertension 2001; 38: 343.","journal-title":"Hypertension"},{"key":"BFhr201685_CR52","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF00374478","volume":"420","author":"C Romanin","year":"1992","unstructured":"Romanin C, Seydl K, Glossmann H, Schindler H . Activity of cardiac L-type Ca2+ channels is sensitive to cytoplasmic calcium. Pflugers Arch 1992; 420: 410.","journal-title":"Pflugers Arch"},{"key":"BFhr201685_CR53","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0022-3565(24)35127-4","volume":"291","author":"T Furukawa","year":"1999","unstructured":"Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T . Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999; 291: 464.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFhr201685_CR54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejphar.2009.04.036","volume":"613","author":"T Furukawa","year":"2009","unstructured":"Furukawa T, Nukada T, Namiki Y, Miyashita Y, Hatsuno K, Ueno Y, Yamakawa T, Isshiki T . Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes. Eur J Pharmacol 2009; 613: 100\u2013107.","journal-title":"Eur J Pharmacol"},{"key":"BFhr201685_CR55","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/01.RES.0000256155.31133.49","volume":"100","author":"K Hayashi","year":"2007","unstructured":"Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T . Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342.","journal-title":"Circ Res"},{"key":"BFhr201685_CR56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1254\/jphs.FMJ05002X6","volume":"99","author":"K Hayashi","year":"2005","unstructured":"Hayashi K, Wakino S, Homma K, Sugano N, Saruta T . Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci 2005; 99: 221.","journal-title":"J Pharmacol Sci"},{"key":"BFhr201685_CR57","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/hr.2009.78","volume":"32","author":"T Tsutamoto","year":"2009","unstructured":"Tsutamoto T, Tanaka T, Nishiyama K, Yamaji M, Kawahara C, Fujii M, Yamamoto T, Horie M . Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertens Res 2009; 32: 670\u2013674.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8227(01)00288-1","volume":"54","author":"S Baba","year":"2001","unstructured":"Baba S, J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191\u2013201.","journal-title":"Diabetes Res Clin Pract"},{"key":"BFhr201685_CR59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjhyper.2006.10.002","volume":"20","author":"R Fogari","year":"2007","unstructured":"Fogari R, Derosa G, Zoppi A, Preti P, Lazzari P, Destro M, Fogari E, Rinaldi A, Mugellini A . Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007; 20: 417\u2013422.","journal-title":"Am J Hypertens"},{"key":"BFhr201685_CR60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF00580754","volume":"31","author":"C Schnack","year":"1994","unstructured":"Schnack C, Capek M, Banyai M, Kautzky-Willer A, Prager R, Schernthaner G . Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta Diabetol 1994; 31: 14\u201318.","journal-title":"Acta Diabetol"},{"key":"BFhr201685_CR61","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00004872-200103000-00020","volume":"19","author":"SM Voyaki","year":"2001","unstructured":"Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenh\u00e4ger WH, de Leeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001; 19: 511\u2013519.","journal-title":"J Hypertens"},{"key":"BFhr201685_CR62","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.HYP.34.5.1129","volume":"34","author":"National Intervention Cooperative Study in Elderly Hypertensives Study Group","year":"1999","unstructured":"National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129\u20131133.","journal-title":"Hypertension"},{"key":"BFhr201685_CR63","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","volume":"356","author":"MJ Brown","year":"2000","unstructured":"Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM . Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366\u2013372.","journal-title":"Lancet"},{"key":"BFhr201685_CR64","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981\u20132997.","journal-title":"JAMA"},{"key":"BFhr201685_CR65","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Brigs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S, African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719\u20132728.","journal-title":"JAMA"},{"key":"BFhr201685_CR66","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00004872-200110000-00023","volume":"19","author":"R Marin","year":"2001","unstructured":"Marin R, Ruilope LM, Aljama P, Aranda P, Segura J, Diez J, Investigators of the ESPIRAL Study. Efecto del tratamiento antihipertensivo Sobre la Progresi\u00f3n de la Insuficiencia RenAL en pacientes no diab\u00e9ticos. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19: 1871\u20131876.","journal-title":"J Hypertens"},{"key":"BFhr201685_CR67","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clinthera.2008.03.006","volume":"30","author":"VL Esnault","year":"2008","unstructured":"Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, Dechatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: A 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2008; 30: 482\u2013498.","journal-title":"Clin Ther"},{"key":"BFhr201685_CR68","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/08860220701643559","volume":"29","author":"S Ziakka","year":"2007","unstructured":"Ziakka S, Kaperonis N, Ferentinou E, Karakasis P, Ntatsis G, Kourvelou C, Papagalanis N . Calcium channels blockers and progression of kidney disease. Ren Fail 2007; 29: 1003\u20131012.","journal-title":"Ren Fail"},{"key":"BFhr201685_CR69","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1291\/hypres.31.841","volume":"31","author":"T Nakamura","year":"2008","unstructured":"Nakamura T, Inoue T, Suzuki T, Kawagoe Y, Ueda Y, Koide H, Node K . Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res 2008; 31: 841\u2013850.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR70","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851\u2013860.","journal-title":"N Engl J Med"},{"key":"BFhr201685_CR71","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005; 366: 895\u2013906.","journal-title":"Lancet"},{"key":"BFhr201685_CR72","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/ndt\/16.11.2158","volume":"16","author":"H Herlitz","year":"2001","unstructured":"Herlitz H, Harris K, Risler T, Bonner G, Bernheim J, Channard J, Aurell M . The effect of an ACE inhibitor and a calcium antagonist in the progression of renal disease: the Nephros study. Nephrol Dial Transplant 2001; 16: 2158\u20132165.","journal-title":"Nephrol Dial Transplant"},{"key":"BFhr201685_CR73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1291\/hypres.23.219","volume":"23","author":"T Shigihara","year":"2000","unstructured":"Shigihara T, Sato A, Hayashi K, Saruta T . Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes. Hypertens Res 2000; 23: 219\u2013226.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR74","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0895-7061(02)03017-0","volume":"15","author":"R Fogari","year":"2002","unstructured":"Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, Poletti L, Marasi G, Derosa G, Mugellini A, Voglini C, Lazzari P . Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 1042\u20131049.","journal-title":"Am J Hypertens"},{"key":"BFhr201685_CR75","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","volume":"365","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M . Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939\u2013946.","journal-title":"Lancet"},{"key":"BFhr201685_CR76","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2008.102","volume":"73","author":"GL Bakris","year":"2008","unstructured":"Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study Investigators. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303\u20131309.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR77","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahl\u00f6f B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk. patients. N Engl J Med 2008; 359: 2417\u20132428.","journal-title":"N Engl J Med"},{"key":"BFhr201685_CR78","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","volume":"375","author":"GL Bakris","year":"2010","unstructured":"Bakris GL, Sarafidis PA, Weir MR, Dahl\u00f6f B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial investigators for the ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173\u20131181.","journal-title":"Lancet"},{"key":"BFhr201685_CR79","unstructured":"Sarafidis PA, Bakris G, Weber M, Pitt B, Dahlof B, Velazquez EJ, Shi V, Hester A, Gupte J, Gatlin M . Changes in glomerular filtration rate with benazepril plus amlodipine or benazepril plus hydrochlorothiazide treatment in hypertensive patients at high cardiovascular risk; an analysis of the ACCOMPLISH trial. http:\/\/www.abstracts2viewcom\/wcn\/viewphp?nu=WCN09L_4552009. Accessed 30 November 2010."},{"key":"BFhr201685_CR80","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc1001410","volume":"363","author":"KA Jamerson","year":"2010","unstructured":"Jamerson KA, Bakris GL, Weber MA . 24-h ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med 2010; 363: 98.","journal-title":"N Engl J Med"},{"key":"BFhr201685_CR81","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1081\/JDI-120024284","volume":"25","author":"G Bellinghieri","year":"2003","unstructured":"Bellinghieri G, Mazzaglia G, Savica V, Santoro D . Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren Fail 2003; 25: 681\u2013689.","journal-title":"Ren Fail"},{"key":"BFhr201685_CR82","first-page":"261","volume":"17","author":"L Del Vecchio","year":"2004","unstructured":"Del Vecchio L, Pozzi M, Salvetti A, Maschio G, Fusaroli M, Rovati C, Antonucci F, Cascone C, Scanferla F, Panichi V, Sturani A, Locatelli F, Manidipine Study Group. Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril. J Nephrol 2004; 17: 261\u2013269.","journal-title":"J Nephrol"},{"key":"BFhr201685_CR83","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00228-005-0961-2","volume":"61","author":"R Fogari","year":"2005","unstructured":"Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P . Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur J Clin Pharmacol 2005; 61: 483\u2013490.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFhr201685_CR84","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1586\/14779072.6.10.1347","volume":"6","author":"FJ Martinez-Martin","year":"2008","unstructured":"Martinez-Martin FJ, Saiz-Satjes M . Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev Cardiovasc Ther 2008; 6: 1347\u20131355.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"BFhr201685_CR85","first-page":"259","volume":"17","author":"M Dalla Vestra","year":"2004","unstructured":"Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, Crepaldi G . Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type II diabetic patients with microalbuminuria: DIAL Study (diabete, ipertensione, albuminuria, lercanidipina). Diab Nutr Metab 2004; 17: 259\u2013266.","journal-title":"Diab Nutr Metab"},{"key":"BFhr201685_CR86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1081\/JDI-42801","volume":"27","author":"NR Robles","year":"2005","unstructured":"Robles NR, Ocon J, Gomez Campder\u00e1 F, Manjon M, Pastor L, Herrera J, Villatoro J, Calls J, Torrijos J, Rodr\u00edguez VI, Rodriguez MM, Mendez ML, Morey A, Martinez FI, Marco J, Liebana A, Rincon B, Tornero F . Lercanidipine in chronic renal failure patients: the ZAFRA study. Ren Fail 2005; 27: 73\u201380.","journal-title":"Ren Fail"},{"key":"BFhr201685_CR87","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/08860220903541135","volume":"32","author":"NR Robles","year":"2010","unstructured":"Robles NR, Romero B, Garcia de Vinuesa E, S\u00e1nchez-Casado E, Cubero JJ . Treatment of proteinuria with lercanidipine associated to renin-angiotensin axis blocking drugs. Ren Fail 2010; 32: 192\u2013197.","journal-title":"Ren Fail"},{"key":"BFhr201685_CR88","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1291\/hypres.30.621","volume":"30","author":"T Ichitmitsu","year":"2007","unstructured":"Ichitmitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H . Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621\u2013626.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR89","doi-asserted-by":"crossref","first-page":"568","DOI":"10.5551\/jat.1628","volume":"16","author":"H Sasaki","year":"2009","unstructured":"Sasaki H, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H, Nagayama D, Ohhira M, Oyama T, Miyashita Y, Shirai K . Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb 2009; 16: 568\u2013575.","journal-title":"J Atheroscler Thromb"},{"key":"BFhr201685_CR90","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0895-7061(02)03147-3","volume":"16","author":"K Hayashi","year":"2003","unstructured":"Hayashi K, Kumagai H, Saruta T . Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116\u2013122.","journal-title":"Am J Hypertens"},{"key":"BFhr201685_CR91","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/10641960500298558","volume":"27","author":"T Tsuchihashi","year":"2005","unstructured":"Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, Goto K . Antiproteinuric effect of N type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005; 27: 583\u2013591.","journal-title":"Clin Exp Hypertens"},{"key":"BFhr201685_CR92","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1291\/hypres.24.377","volume":"24","author":"GW Rose","year":"2001","unstructured":"Rose GW, Ikebukoro H . Cilnidipine as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24: 377\u2013383.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1291\/hypres.27.379","volume":"27","author":"S Kojima","year":"2004","unstructured":"Kojima S, Shida M, Yokoyama H . Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27: 379\u2013385.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR94","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.ki.5000349","volume":"70","author":"K Katayama","year":"2006","unstructured":"Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T . Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int 2006; 70: 151\u2013156.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR95","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.ki.5002623","volume":"72","author":"T Fujita","year":"2007","unstructured":"Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators. Antiproteinuric effect of calcium channel blocker cilnidipine added to renin angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543\u20131549.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR96","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.7150\/ijms.5508","volume":"10","author":"K Ando","year":"2013","unstructured":"Ando K, Ueshima K, Tanaka T, Kosugi S, Sato T, Matsuoka H, Nakao K, Fujita T . Comparison of the antialbuminuric effects of L-\/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the Study of Assessment for Kidney Function by Urinary Microalbumin in Randomized (SAKURA) Trial. Int J Med Sci 2013; 10: 1209\u20131216.","journal-title":"Int J Med Sci"},{"key":"BFhr201685_CR97","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/10641961003667914","volume":"32","author":"Y Miwa","year":"2010","unstructured":"Miwa Y, Tsuchihashi T, Ohta Y, Tominaga M, Kawano Y, Sasaguri T, Ueno M, Matsuoka H . Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors-a multicenter, open, randomized trial using 24-hour urine collection. Clin Exp Hypertens 2010; 32: 400\u2013405.","journal-title":"Clin Exp Hypertens"},{"key":"BFhr201685_CR98","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/hr.2010.221","volume":"34","author":"M Abe","year":"2011","unstructured":"Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M . Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34: 268\u2013273.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR99","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/hr.2009.11","volume":"32","author":"M Abe","year":"2009","unstructured":"Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K . Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3\u20135 chronic kidney disease. Hypertens Res 2009; 32: 270\u2013275.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR100","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1517\/13543784.2010.505918","volume":"19","author":"M Abe","year":"2010","unstructured":"Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M . Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. Expert Opin Investig Drugs 2010; 19: 1027\u20131037.","journal-title":"Expert Opin Investig Drugs"},{"key":"BFhr201685_CR101","doi-asserted-by":"crossref","first-page":"756","DOI":"10.5301\/JN.2011.6383","volume":"24","author":"Y Tomino","year":"2011","unstructured":"Tomino Y, Shimizu Y, Hamada C, Kurusu A, Ohsawa I, Suzuki Y, Tsuge T, Io H, Kobayashi N, Takeda Y, Asanuma K, Tanaka Y, Suzuki H, Nakata J, Takara K, Horikoshi S . One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease. J Nephrol 2011; 24: 756\u2013763.","journal-title":"J Nephrol"},{"key":"BFhr201685_CR102","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/hr.2015.69","volume":"38","author":"N Thamcharoen","year":"2015","unstructured":"Thamcharoen N, Susantitaphong P, Wongrakpanich S, Chongsathidkiet P, Tantrachoti P, Pitukweerakul S, Avihingsanon Y, Praditpornsilpa K, Jaber BL, Eiam-Ong S . Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis. Hypertens Res 2015; 38: 847\u2013855.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR103","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/clpt.1994.143","volume":"56","author":"G Ranieri","year":"1994","unstructured":"Ranieri G, Andriani A, Lamontanara G, De Cesaris R . Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther 1994; 56: 323\u2013330.","journal-title":"Clin Pharmacol Ther"},{"key":"BFhr201685_CR104","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1291\/hypres.27.21","volume":"27","author":"Y Iino","year":"2004","unstructured":"Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchii Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators. Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension\u2014a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21\u201330.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR105","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1291\/hypres.25.849","volume":"25","author":"S Kuriyama","year":"2002","unstructured":"Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T . Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2002; 25: 849\u2013855.","journal-title":"Hypertens Res"},{"key":"BFhr201685_CR106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0272-6386(00)70195-8","volume":"35","author":"T Ecder","year":"2000","unstructured":"Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW . Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35: 427\u2013432.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 68","key":"BFhr201685_CR107","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1038\/sj.ki.4490576","volume":"54","author":"C Fernandez Andrade","year":"1998","unstructured":"Fernandez Andrade C, Russo D, Iversen B, Zucchelli P, Aranda P, Guerra L, Casado S . Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int 1998; 54 (Suppl 68): S120\u2013S124.","journal-title":"Kidney Int"},{"key":"BFhr201685_CR108","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NG, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure\u2013independent effect. Circulation 2002; 106: 672\u2013678.","journal-title":"Circulation"},{"key":"BFhr201685_CR109","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Br\u00f6chner-Mortensen J, Gomis R, Andersen S . Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870\u2013878.","journal-title":"N Engl J Med"},{"key":"BFhr201685_CR110","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/ndt\/gfg284","volume":"18","author":"M Praga","year":"2003","unstructured":"Praga M, Fernandez Andrade C, Lu\u00f1o J, Arias M, Poveda R, Mora J, Prat MV, Rivera F, Galceran JM, Ara JM, Aguirre R, Bernis C, Mar\u00edn R, Campistol JM . l. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomised clinical trial. Nephrol Dial Transplant 2003; 18: 1806\u20131813.","journal-title":"Nephrol Dial Transplant"},{"key":"BFhr201685_CR111","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2337\/diacare.21.1.104","volume":"21","author":"G Crepaldi","year":"1998","unstructured":"Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F . Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998; 21: 104\u2013110.","journal-title":"Diabetes Care"},{"key":"BFhr201685_CR112","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00838494","volume":"32","author":"G Crepaldi","year":"1995","unstructured":"Crepaldi G, Carraro A, Brocco E, Adezati L, Andreani D, Bompiani G, Brunetti P, Fedele D, Giorgino R, Giustina G . Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol 1995; 32: 203\u2013208.","journal-title":"Acta Diabetol"},{"key":"BFhr201685_CR113","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000188911","volume":"72","author":"M Giordano","year":"1996","unstructured":"Giordano M, Sanders LR, Castellino P, Canessa ML, DeFronzo RA . Effect of alpha-adrenergic blockers, ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients. Nephron 1996; 72: 447\u2013453.","journal-title":"Nephron"},{"key":"BFhr201685_CR114","first-page":"333","volume":"7","author":"MJ O'Donnell","year":"1993","unstructured":"O'Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH . Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. J Hum Hypertens 1993; 7: 333\u2013339.","journal-title":"J Hum Hypertens"},{"key":"BFhr201685_CR115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bmj.302.6770.210","volume":"302","author":"Melbourne Diabetic Nephropathy Study Group","year":"1991","unstructured":"Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302: 210\u2013216.","journal-title":"BMJ"},{"key":"BFhr201685_CR116","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000049038","volume":"90","author":"G Leoncini","year":"2002","unstructured":"Leoncini G, Martinoli C, Viazzi F, Ravera M, Parodi D, Ratto E, Vettoretti S, Tomolillo C, Derchi LE, Deferrari G, Pontremoli R . Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS. Nephron 2002; 90: 169\u2013173.","journal-title":"Nephron"},{"key":"BFhr201685_CR117","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0272-6386(05)80003-4","volume":"37","author":"G Jerums","year":"2001","unstructured":"Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J, Tsalamandris C, Melbourne Diabetic Nephropathy Study Group. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Am J Kidney Dis 2001; 37: 890\u20138990.","journal-title":"Am J Kidney Dis"},{"issue":"2 Suppl","key":"BFhr201685_CR118","first-page":"II237","volume":"19","author":"L Ferder","year":"1992","unstructured":"Ferder L, Daccordi H, Martello M, Panzalis M, Inserra F . Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19 (2 Suppl): II237\u2013II242.","journal-title":"Hypertension"},{"key":"BFhr201685_CR119","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/bmj.305.6860.981","volume":"305","author":"JC Chan","year":"1992","unstructured":"Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R . Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ 1992; 305: 981\u2013985.","journal-title":"BMJ"},{"key":"BFhr201685_CR120","first-page":"115","volume":"23","author":"H Bilo","year":"1993","unstructured":"Bilo H, Kluitman E, van Ballegooie E, Potter van Loon BJ, Bakker K, Michels B, Gans R, Donker A . Long term use of captopril or nifedipine in normotensive microalbuminuric patients with insulin-dependent diabetes mellitus. Diabetes Res 1993; 23: 115\u2013122.","journal-title":"Diabetes Res"},{"key":"BFhr201685_CR121","first-page":"185","volume":"10","author":"CD Agardh","year":"1996","unstructured":"Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH . Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185\u2013192.","journal-title":"J Hum Hypertens"},{"key":"BFhr201685_CR122","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2337\/diabetes.50.4.843","volume":"50","author":"The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT) Study Group","year":"2001","unstructured":"The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT) Study Group. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria. The European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes 2001; 50: 843\u2013850.","journal-title":"Diabetes"},{"key":"BFhr201685_CR123","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.jhh.1000732","volume":"13","author":"R Fogari","year":"1999","unstructured":"Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, Lusardi P . Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47\u201353.","journal-title":"J Hum Hypertens"},{"key":"BFhr201685_CR124","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","volume":"61","author":"RW Schrier","year":"2002","unstructured":"Schrier RW, Estacio RO, Esler A, Mehler P . Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086\u20131097.","journal-title":"Kidney Int"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/hr201685.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/hr201685","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/hr201685.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T01:01:38Z","timestamp":1748998898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr201685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFhr201685"],"URL":"https:\/\/doi.org\/10.1038\/hr.2016.85","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]},"assertion":[{"value":"26 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}